(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of -5.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.21%.
Moderna's revenue in 2025 is $3,078,000,000.On average, 27 Wall Street analysts forecast MRNA's revenue for 2025 to be $752,091,170,281, with the lowest MRNA revenue forecast at $587,510,433,070, and the highest MRNA revenue forecast at $896,828,839,885. On average, 27 Wall Street analysts forecast MRNA's revenue for 2026 to be $835,743,318,036, with the lowest MRNA revenue forecast at $510,861,720,941, and the highest MRNA revenue forecast at $1,232,215,590,419.
In 2027, MRNA is forecast to generate $1,042,344,669,003 in revenue, with the lowest revenue forecast at $608,909,819,705 and the highest revenue forecast at $1,405,745,162,041.